Quick Answer
NEOGENOMICS INC reported Cash and Equivalents of $159.62 million for fiscal year 2025.
NEOGENOMICS INC Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $159.62M | -56.5% |
| 2024 | $367.01M | +7.2% |
| 2023 | $342.49M | +30.1% |
| 2022 | $263.18M | -16.9% |
| 2021 | $316.83M | +38.5% |
| 2020 | $228.71M | +32.2% |
| 2019 | $173.02M | +1663.5% |
| 2018 | $9.81M | -23.5% |
| 2017 | $12.82M | +2.4% |
| 2016 | $12.53M | -46.5% |
| 2015 | $23.42M | -30.5% |
| 2014 | $33.69M | +596.9% |
| 2013 | $4.83M | +158.8% |
| 2012 | $1.87M | -28.9% |
| 2011 | $2.63M | +139.6% |
| 2010 | $1.10M | -32.7% |
| 2009 | $1.63M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $164.12M | -54.7% | +6.1% |
| June 30, 2025 | $154.72M | -56.4% | -55.3% |
| March 31, 2025 | $346.19M | +4.3% | -5.7% |
| December 31, 2024 | $367.01M | +7.2% | +1.4% |
| September 30, 2024 | $361.99M | +18.2% | +1.9% |
| June 30, 2024 | $355.08M | +22.8% | +7.0% |
| March 31, 2024 | $331.91M | +20.4% | -3.1% |
| December 31, 2023 | $342.49M | +30.1% | +11.8% |
- NEOGENOMICS INC showed a decrease of -56.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2009–2025 period, NEOGENOMICS INC’s cash and equivalents has grown by 9686.5% (from $1.63 million to $159.62 million).
- The most recent figure is from NEOGENOMICS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: